Literature DB >> 9203425

Use of inhaled corticosteroids and the risk of cataracts.

R G Cumming1, P Mitchell, S R Leeder.   

Abstract

BACKGROUND: The use of systemic corticosteroids is a risk factor for the development of posterior subcapsular cataracts, but the association between inhaled corticosteroids and cataracts is uncertain.
METHODS: We conducted a population-based, cross-sectional study of vision and common eye diseases in an urban area of the Blue Mountains, near Sydney, Australia. We recruited 3654 people 49 to 97 years of age; the participation rate was 82 percent. We collected information by questionnaire on potential risk factors for cataracts, including the current or prior use of inhaled corticosteroids (beclomethasone or budesonide). Photographs of the subjects' lenses were graded, without information on the subjects, to determine the presence and severity of cortical, nuclear, and posterior subcapsular cataracts.
RESULTS: Three hundred seventy subjects reported using inhaled corticosteroids, 164 currently and 206 previously. Among these subjects, after adjustment for age and sex, there was a higher prevalence of nuclear cataracts (relative prevalence, 1.5; 95 percent confidence interval, 1.2 to 1.9) and posterior subcapsular cataracts (relative prevalence, 1.9; 95 percent confidence interval, 1.3 to 2.8) than among the subjects with no inhaled-corticosteroid use, but the prevalence of cortical cataracts was not significantly higher (relative prevalence, 1.1; 95 percent confidence interval, 0.9 to 1.3). Higher cumulative lifetime doses of beclomethasone were associated with higher risks of posterior subcapsular cataracts (P for trend <0.001); the highest prevalence (27 percent) was found in subjects whose lifetime dose was over 2000 mg (relative prevalence, 5.5). Adjusting for the use of systemic corticosteroids and other potential confounders had little effect on the magnitude of the associations. The associations with posterior subcapsular cataracts, but not those with nuclear cataracts, were less marked when the analyses were restricted to subjects who had never used systemic corticosteroids.
CONCLUSIONS: The use of inhaled corticosteroids is associated with the development of posterior subcapsular and nuclear cataracts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203425     DOI: 10.1056/NEJM199707033370102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  84 in total

Review 1.  A systematic review of drug induced ocular reactions in diabetes.

Authors:  J P Hampson; J N Harvey
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

2.  Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects.

Authors:  T W Harrison; A Wisniewski; J Honour; A E Tattersfield
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

3.  Chronic asthma.

Authors:  C Cates
Journal:  BMJ       Date:  2001-10-27

4.  Treating children with asthma. A review of drug therapies.

Authors:  H Kalister
Journal:  West J Med       Date:  2001-06

5.  Inhaled corticosteroids and the risk of diabetes among the elderly.

Authors:  Nandini Dendukuri; Lucie Blais; Jacques LeLorier
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

6.  Glucocorticoids in the treatment of early and late RA.

Authors:  J W J Bijlsma; M Boers; K G Saag; D E Furst
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

7.  A population based case-control study of cataract and inhaled corticosteroids.

Authors:  L Smeeth; M Boulis; R Hubbard; A E Fletcher
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

8.  Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis.

Authors:  Songshi Ni; Zhenxue Fu; Jing Zhao; Hua Liu
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

Review 9.  Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Authors:  K Suresh Babu; Jack A Kastelik; Jaymin B Morjaria
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

10.  Risk of adverse gastrointestinal events from inhaled corticosteroids.

Authors:  Richard A Hansen; Wanzhu Tu; Jane Wang; Roberta Ambuehl; Clement J McDonald; Michael D Murray
Journal:  Pharmacotherapy       Date:  2008-11       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.